Ipamorelin
Growth hormone secretagogue (ghrelin/growth hormone secretagogue receptor agonist)
What It Is
A synthetic peptide designed to stimulate growth hormone release via the ghrelin receptor pathway, often discussed alongside CJC-1295 in research/community contexts as a combination.
Proposed Mechanism
Activates the growth hormone secretagogue receptor, prompting pulsatile growth hormone release from the pituitary, with a proposed selectivity profile intended to minimize effects on other hormones (e.g., cortisol) compared to older secretagogues — this selectivity claim originates in early pharmacology research and should be attributed and hedged accordingly, not stated as settled fact.
Areas Researchers Are Investigating
- Growth hormone secretion selectivity
- Potential body-composition and recovery-related research questions (largely community-driven interest)
Human Evidence
Limited public large-scale controlled trial data. Related secretagogue-class compounds have more extensive study in specific diagnostic contexts, but that should not be conflated with evidence specific to ipamorelin itself.
Animal / Preclinical Evidence
Receptor-binding and endocrine pharmacology studies form the bulk of the available preclinical picture.
Current FDA / Regulatory Status
Not FDA-approved as a standalone product for any indication.
Known Safety Information
No comprehensive controlled human safety database exists publicly at drug-approval scale. General hormone-axis manipulation carries risks that require licensed medical supervision to assess — not something to characterize as safe or unsafe in a general-audience article without that caveat.
Limitations of Evidence
Sparse controlled human trials; much of the public discussion is anecdotal rather than clinical-trial-derived.